Circulating lipoprotein (a) and all-cause and cause-specific mortality : a systematic review and dose-response meta-analysis
© 2023. The Author(s)..
AIMS: To investigate the association between circulating lipoprotein(a) (Lp(a)) and risk of all-cause and cause-specific mortality in the general population and in patients with chronic diseases, and to elucidate the dose-response relations.
METHODS AND RESULTS: We searched literature to find prospective studies reporting adjusted risk estimates on the association of Lp(a) and mortality outcomes. Forty-three publications, reporting on 75 studies (957,253 participants), were included. The hazard ratios (HRs) and 95% confidence intervals (95%CI ) for the top versus bottom tertile of Lp(a) levels and risk of all-cause mortality were 1.09 (95%CI: 1.01-1.18, I2: 75.34%, n = 19) in the general population and 1.18 (95%CI: 1.04-1.34, I2: 52.5%, n = 12) in patients with cardiovascular diseases (CVD). The HRs for CVD mortality were 1.33 (95%CI: 1.11-1.58, I2: 82.8%, n = 31) in the general population, 1.25 (95%CI: 1.10-1.43, I2: 54.3%, n = 17) in patients with CVD and 2.53 (95%CI: 1.13-5.64, I2: 66%, n = 4) in patients with diabetes mellitus. Linear dose-response analyses revealed that each 50 mg/dL increase in Lp(a) levels was associated with 31% and 15% greater risk of CVD death in the general population and in patients with CVD. No non-linear dose-response association was observed between Lp(a) levels and risk of all-cause or CVD mortality in the general population or in patients with CVD (Pnonlinearity > 0.05).
CONCLUSION: This study provides further evidence that higher Lp(a) levels are associated with higher risk of all-cause mortality and CVD-death in the general population and in patients with CVD. These findings support the ESC/EAS Guidelines that recommend Lp(a) should be measured at least once in each adult person's lifetime, since our study suggests those with higher Lp(a) might also have higher risk of mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
European journal of epidemiology - 38(2023), 5 vom: 28. Mai, Seite 485-499 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amiri, Mojgan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
Date Completed 08.05.2023 Date Revised 09.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10654-022-00956-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352188405 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352188405 | ||
| 003 | DE-627 | ||
| 005 | 20231226053138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10654-022-00956-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352188405 | ||
| 035 | |a (NLM)36708412 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amiri, Mojgan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating lipoprotein (a) and all-cause and cause-specific mortality |b a systematic review and dose-response meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.05.2023 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a AIMS: To investigate the association between circulating lipoprotein(a) (Lp(a)) and risk of all-cause and cause-specific mortality in the general population and in patients with chronic diseases, and to elucidate the dose-response relations | ||
| 520 | |a METHODS AND RESULTS: We searched literature to find prospective studies reporting adjusted risk estimates on the association of Lp(a) and mortality outcomes. Forty-three publications, reporting on 75 studies (957,253 participants), were included. The hazard ratios (HRs) and 95% confidence intervals (95%CI ) for the top versus bottom tertile of Lp(a) levels and risk of all-cause mortality were 1.09 (95%CI: 1.01-1.18, I2: 75.34%, n = 19) in the general population and 1.18 (95%CI: 1.04-1.34, I2: 52.5%, n = 12) in patients with cardiovascular diseases (CVD). The HRs for CVD mortality were 1.33 (95%CI: 1.11-1.58, I2: 82.8%, n = 31) in the general population, 1.25 (95%CI: 1.10-1.43, I2: 54.3%, n = 17) in patients with CVD and 2.53 (95%CI: 1.13-5.64, I2: 66%, n = 4) in patients with diabetes mellitus. Linear dose-response analyses revealed that each 50 mg/dL increase in Lp(a) levels was associated with 31% and 15% greater risk of CVD death in the general population and in patients with CVD. No non-linear dose-response association was observed between Lp(a) levels and risk of all-cause or CVD mortality in the general population or in patients with CVD (Pnonlinearity > 0.05) | ||
| 520 | |a CONCLUSION: This study provides further evidence that higher Lp(a) levels are associated with higher risk of all-cause mortality and CVD-death in the general population and in patients with CVD. These findings support the ESC/EAS Guidelines that recommend Lp(a) should be measured at least once in each adult person's lifetime, since our study suggests those with higher Lp(a) might also have higher risk of mortality | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Cause of death | |
| 650 | 4 | |a Chronic disease | |
| 650 | 4 | |a Cohort studies | |
| 650 | 4 | |a Heart disease risk factors | |
| 650 | 4 | |a Lipoprotein(a) | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Lipoprotein(a) |2 NLM | |
| 700 | 1 | |a Raeisi-Dehkordi, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Verkaar, Auke J C F |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yahong |e verfasserin |4 aut | |
| 700 | 1 | |a van Westing, Anniek C |e verfasserin |4 aut | |
| 700 | 1 | |a Berk, Kirsten A |e verfasserin |4 aut | |
| 700 | 1 | |a Bramer, Wichor M |e verfasserin |4 aut | |
| 700 | 1 | |a Aune, Dagfinn |e verfasserin |4 aut | |
| 700 | 1 | |a Voortman, Trudy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of epidemiology |d 1986 |g 38(2023), 5 vom: 28. Mai, Seite 485-499 |w (DE-627)NLM012646482 |x 1573-7284 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:5 |g day:28 |g month:05 |g pages:485-499 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10654-022-00956-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 5 |b 28 |c 05 |h 485-499 | ||